Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Issue 16 (12th April 2018)

• Record Type: Journal Article
• Authors: Chen, C.; Beutels, P.; Newall, A.T.
• Is Part Of: Vaccine. Volume 36:Issue 16(2018)
• Page Start: 2057
• Page End: 2060
• Publication Date: 2018-04-12
• Subjects: PCV13 -- Pneumonia -- Herd immunity -- Immunization -- Markov model -- Evolution of serotype; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.03.006
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: In many settings, serotype changes as a result of infant 13-valent pneumococcal conjugate vaccine (PCV13) programs are likely to continue after the introduction of adult PCV13 programs. We applied a multi-cohort model to explore how potential serotype changes may impact on the cost-effectiveness of PCV13 use in Australian adults aged over 65 years. We found assumptions around continued herd protection from infant PCV13 programs to be critical when assessing the cost-effectiveness of adult PCV13 vaccination in Australia. Future cost-effectiveness analyses of adult PCV13 programs need to carefully consider how to predict these future changes in serotypes, with Australian data suggesting that the changes post-PCV13 use in infants may be different than post-PCV7.